Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference
28 2월 2023 - 8:00PM
Business Wire
Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic
solutions company with a focus in lung disease, announced today
that Scott Hutton, Chief Executive Officer of Biodesix, will
participate in a fireside chat and host in-person 1x1 investor
meetings at Cowen’s 43rd Annual Healthcare Conference being held
from March 6-8, 2023.
Cowen’s 43rd Annual Healthcare Conference Fireside Chat
Date: Tuesday, March 7, 2023 Fireside Chat Time: 1:30 PM ET
Location: Boston Marriott Copley Place
The fireside chat will be webcast live and available for replay
under “News & Events” in the Investors section of the Company's
website at www.biodesix.com.
About Biodesix Biodesix is a leading data-driven
diagnostic solutions company with a focus in lung disease. The
Company develops diagnostic tests addressing important clinical
questions by combining multi-omics through the power of artificial
intelligence. Biodesix offers five Medicare-covered tests for
patients with lung diseases. The blood based Nodify Lung® nodule
risk assessment testing strategy, consisting of the Nodify XL2® and
the Nodify CDT® tests, evaluates the risk of malignancy in
pulmonary nodules, enabling physicians to better triage patients to
the most appropriate course of action. The blood based IQLung™
strategy for lung cancer patients integrates the GeneStrat®
targeted ddPCR™ test, the GeneStrat NGS™ test and the VeriStrat®
test to support treatment decisions across all stages of lung
cancer with results in an average of two to three business days,
expediting time to treatment. Biodesix also leverages the
proprietary and advanced Diagnostic Cortex® AI (Artificial
Intelligence) platform, to collaborate with many of the world’s
leading biotechnology and pharmaceutical companies to solve complex
diagnostic challenges in lung disease. For more information about
Biodesix, visit biodesix.com.
Note Regarding Forward-Looking Statements This press
release may contain forward-looking statements that involve
substantial risks and uncertainties for purposes of the safe harbor
provided by the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release other than
statements of historical fact, are forward-looking statements. The
words “believe,” “may,” “will,” “estimate,” “continue,”
“anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,”
“opportunity,” “goals,” or “should,” and similar expressions are
intended to identify forward-looking statements. Such statements
are based on management’s current expectations and involve risks
and uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors. Biodesix has based these
forward-looking statements largely on its current expectations and
projections about future events and trends. These forward-looking
statements are subject to a number of risks, uncertainties, and
assumptions. Forward-looking statements may include information
concerning the impact of the COVID-19 pandemic on Biodesix and its
operations, its possible or assumed future results of operations,
including descriptions of its revenues, profitability, outlook, and
overall business strategy. Forward-looking statements are
inherently subject to risks and uncertainties, some of which cannot
be predicted or quantified. The Company's ability to continue as a
going concern could cause actual results to differ materially from
those contemplated in this press release and additionally, other
factors that could cause actual results to differ materially from
those contemplated in this press release can be found in the Risk
Factors section of Biodesix’s most recent annual report on Form
10-K, filed March 14, 2022 or subsequent quarterly reports on Form
10-Q during 2022, if applicable. Biodesix undertakes no obligation
to revise or publicly release the results of any revision to such
forward-looking statements, except as required by law. Given these
risks and uncertainties, readers are cautioned not to place undue
reliance on such forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230228005454/en/
Media: Robin Harper Cowie robin.cowie@biodesix.com (720)
509-8841
Investors: Chris Brinzey chris.brinzey@westwicke.com
(339) 970-2843
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Biodesix (NASDAQ:BDSX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024